Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety
of LDT600 in pediatric and adolescent patients with chronic hepatitis B infection.